SloveniaThe article discusses challenges in accessing effective treatments for rare diseases in Slovenia, focusing on the case of Elevidys, a gene therapy for Duchenne muscular dystrophy. It highlights criticism of current policies and funding mechanisms, noting that despite efforts to provide access to therapies available abroad, such as Elevidys in the U.S., these treatments remain unavailable in Slovenia due to regulatory and financial barriers. The article mentions the proposed new legislation aimed at improving access but notes that existing laws have failed to deliver results. It also references concerns over the reliability of clinical trial data and potential risks associated with unproven gene therapies. Minister Tadej Ostrc outlines plans for a self-sufficient fund to support such treatments, drawing on multiple funding sources including tax revenues, voluntary industry collaboration, and European funds.
Bias read (Center): While the article presents criticisms of current healthcare policies and highlights disparities in treatment access, it does not exhibit clear ideological leaning. It reports on both the shortcomings of existing systems and the proposed reforms, without overtly favoring either political factions. It
